Summary
78 / 100 · Bulios Score
What speaks for it
- Out of every 100 DKK of revenue, 26 DKK is left as net profit.
- Revenue grew by 23% a year over the last 3 years.
- It holds more cash than debt: 776.7M kr against 131.3M kr.
- You pay 12.8 DKK for 1 DKK of yearly profit, little for its sector.
What to watch
- It missed profit estimates 4 times in the last 8 quarters.
- It earns only 5.7 DKK a year on every 100 DKK of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 12.8 DKK for 1 DKK of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (DKK)
Diluted EPS (DKK)
- Analyst estimate
Revenue grew by 26% a year over 5 years. Over the last 3 years it grew by 23% a year.
Growth in detailDoes it make money?
Very wellWhere 100 DKK of revenue goes
- Cost of sales 51 DKK
- Research and development 11 DKK
- Sales and administration 21 DKK
- Taxes and other -9.1 DKK
- Net profit 26 DKK
Net profit, industry median (Biotechnology) -10 DKK
Out of every 100 DKK of revenue, 26 DKK is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 0
- Hold 1
- Sell 0
No analyst has published a price target.
0.0% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.